Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced inducement grants to eight new employees under its 2024 Inducement Plan. The grants include non-qualified stock options to purchase 85,000 shares of Class A common stock at $21.90 per share and restricted stock units (RSUs) for 45,250 shares.
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting from either August 20 or November 20, 2025. All grants are subject to continued employment with Vera.
Vera Therapeutics (Nasdaq: VERA) ha annunciato concessioni di incentivi a otto nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2024. Le assegnazioni comprendono opzioni azionarie non qualificate per l'acquisto di 85.000 azioni di classe A a $21,90 per azione e unità azionarie vincolate (RSU) per 45.250 azioni.
Le opzioni matureranno in quattro anni: il 25% dopo un anno e il restante importo mensilmente nei successivi 36 mesi. Le RSU matureranno in quattro anni con il 25% che si acquisirà ogni anno a partire dall'20 agosto o dal 20 novembre 2025. Tutte le assegnazioni sono condizionate alla permanenza in servizio presso Vera.
Vera Therapeutics (Nasdaq: VERA) anunció concesiones de incentivos a ocho nuevos empleados bajo su Plan de Incentivos 2024. Las concesiones incluyen opciones sobre acciones no calificadas para comprar 85.000 acciones de clase A a $21,90 por acción y unidades de acciones restringidas (RSU) por 45.250 acciones.
Las opciones se consolidarán durante cuatro años: el 25% después del primer año y el resto mensualmente durante los siguientes 36 meses. Las RSU se consolidarán en cuatro años, con un 25% que se liberará anualmente a partir del 20 de agosto o del 20 de noviembre de 2025. Todas las concesiones están sujetas a la continuidad del empleo en Vera.
Vera Therapeutics (나스�: VERA)� 2024� 유인 계획� 따라 8명의 신입 직원에게 유인 보상� 지급했다고 발표했습니다. � 보상에는 주당 $21.90� 조건으로 클래� A 보통� 85,000주를 매수� � 있는 비공� 스톡옵션� 45,250주의 제한부 주식 단위(RSU)가 포함됩니�.
스톡옵션은 4년에 걸쳐 베스팅되�, 1� � 25%가 베스트되� 나머지� 향후 36개월 동안 매월 베스트됩니다. RSU� 4� 동안 베스팅되� 25%� 2025� 8� 20� 또는 11� 20일부� 매년 베스트됩니다. 모든 보상은 Vera� 계속 재직 중일 것을 조건으로 합니�.
Vera Therapeutics (Nasdaq: VERA) a annoncé des attributions incitatives à huit nouveaux employés dans le cadre de son Plan d'Inducement 2024. Les attributions comprennent des options d'achat d'actions non qualifiées pour acquérir 85 000 actions de classe A à 21,90 $ par action et des unités d'actions restreintes (RSU) pour 45 250 actions.
Les options d'achat d'actions seront acquises sur quatre ans : 25 % après un an, le solde étant acquis mensuellement sur les 36 mois suivants. Les RSU seront acquises sur quatre ans, avec 25 % qui seront acquis chaque année à partir du 20 août ou du 20 novembre 2025. Toutes les attributions sont soumises à la poursuite de l'emploi chez Vera.
Vera Therapeutics (Nasdaq: VERA) gab die Gewährung von Anreizen an acht neue Mitarbeiter im Rahmen seines Inducement-Plans 2024 bekannt. Die Zuweisungen umfassen nicht qualifizierte Aktienoptionen zum Kauf von 85.000 Aktien der Klasse A zu $21,90 pro Aktie sowie Restricted Stock Units (RSUs) für 45.250 Aktien.
Die Aktienoptionen werden über vier Jahre unverfallbar: 25% nach einem Jahr und der Rest monatlich über 36 Monate. Die RSUs vesten ebenfalls über vier Jahre, wobei jeweils 25% jährlich ab dem 20. August oder dem 20. November 2025 freigegeben werden. Alle Zuweisungen stehen unter dem Vorbehalt der weiteren Beschäftigung bei Vera.
- None.
- None.
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 85,000 shares of Class A common stock and restricted stock units (RSUs) underlying 45,250 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees� employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on September 4, 2025 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit .
For more information, please contact: Investor Contact:
Joyce Allaire
LifeSci Advisors 212-915-2569
Media Contact:
Debra Charlesworth Vera Therapeutics 415-854-8051
